Dasatinib
Title: Dasatinib
CAS Registry Number: 302962-49-8
CAS Name: N-(2-Chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide
Manufacturers' Codes: BMS-354825
Molecular Formula: C22H26ClN7O2S
Molecular Weight: 488.01
Percent Composition: C 54.15%, H 5.37%, Cl 7.26%, N 20.09%, O 6.56%, S 6.57%
Literature References: Orally bioactive, ATP-competitive dual inhibitor of Src and Abl kinases. Prepn: J. Das et al., WO 0062778; eidem US 6596746 (2000, 2003 both to Bristol-Myers Squibb); and Src/Abl kinase inhibition study: L. J. Lombardo et al., J. Med. Chem. 47, 6658 (2004). In vivo evaluation vs imatinib-resistant mutants in chronic myeloid leukemia: N. P. Shah et al., Science 305, 399 (2004). Mechanism of action study: M. R. Burgess et al., Proc. Natl. Acad. Sci. USA 102, 3395 (2005). Review of therapeutic potential in chronic myeloid leukemia: T. O'Hare et al., Curr. Opin. Genet. Dev. 16, 92-99 (2006).
Properties: mp 279-280°.
Melting point: mp 279-280°
Therap-Cat: Antineoplastic.
Keywords: Antineoplastic; Tyrosine Kinase Inhibitors.

Others monographs:
DeptropinePropionylpromazineAbrineFerrous Phosphide
AlginOctamethyltrisiloxaneOxalyl ChlorideLanosterol
ScopolinSodium BitartrateBismuth Aluminateα-Bromobenzyl Cyanide
Malachite GreenTriethylamineSulfamethizoleNadolol
©2016 DrugLead US FDA&EMEA